AbbVie Celebrates Official Launch

News
Article

AbbVie, a research-focused, specialty biopharmaceutical company that was spun off from Abbott Pharmaceuticals, was officially launched on Jan. 2, 2013

AbbVie, a research-focused, specialty biopharmaceutical company that was spun off from Abbott, was officially launched on Jan. 2, 2013.  The new company will employ approximately 21,000 people in more than 40 countries, according to AbbVie’s news release.

The new company’s portfolio includes both growth brands and durable performers, including HUMIRA (adalimumab), AndroGel (testosterone gel), Lupron (leuprolide), Synagis (palivizumab, manufactured by MedImmune), Creon (pancrelipase), Synthroid (levothyroxine sodium), Kaletra (lopinavir/ritonavir), Norvir (ritonavir), and Zemplar (paricalcitol). In addition, AbbVie’s pipeline contains compounds in more than 20 mid- to late-stage clinical programs as well as discovery efforts in diseases including Hepatitis C, rheumatoid arthritis, psoriasis, multiple sclerosis, Alzheimer's disease, Parkinson's disease, spondyloarthropathies, multiple myeloma, and endometriosis.

"Our commitment at AbbVie is to build on Abbott's 125-year heritage and address some of the world's most serious health issues," said Richard A. Gonzalez, AbbVie’s chairman of the board and chief executive officer, in the press release. "We intend AbbVie's enduring legacy to be one of finding treatments for patients with serious health care needs."

 

Recent Videos
Drug Digest: Strategic Partnerships
Michelle Bridenbaker from Unbiased Science discusses her thoughts on the key industry from 2024 and those she anticipates will impact the industry in 2025 and beyond.
Tore Bergsteiner from MAIN5 details his predictions for how the mega trends will shape the bio/pharma industry in 2025 and beyond.
Related Content